The prognosis of mBCs has been verified to be better with CDK4/6 plus AI or fulvestrant, especially the early-line use, in Europe [23, 24], the US [25] and East Assia [26–28]. The gene discussed is CDK4; the disease is maternal uniparental disomy of chromosome 20.